標(biāo)題: Titlebook: Cancer Immunotherapies; Solid Tumors and Hem Priya Hays Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive license [打印本頁] 作者: MIFF 時間: 2025-3-21 20:07
書目名稱Cancer Immunotherapies影響因子(影響力)
作者: lobster 時間: 2025-3-21 21:18 作者: EVADE 時間: 2025-3-22 03:22 作者: 死亡 時間: 2025-3-22 07:15
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma,efficacy and safety of CAR T cell therapy in GBM. In this review, common challenges associated with treating GBM will be discussed in addition to how CAR T cells can overcome such barriers. Additionally, emerging techniques of optimizing CAR T cell therapy for GBM will be emphasized, highlighting the prospective promise of cellular immunotherapy.作者: 懶洋洋 時間: 2025-3-22 10:11 作者: 知識分子 時間: 2025-3-22 14:14 作者: 知識分子 時間: 2025-3-22 19:48 作者: 過多 時間: 2025-3-22 22:46 作者: Compassionate 時間: 2025-3-23 03:57
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity,rticularly with the goal of generating Th1-promoting inflammation that stokes endogenous priming of antitumor CD8. T cells, is a growing area of clinical investigation. This approach is analogous to in situ vaccination, ultimately providing a personalized antitumor response against relevant tumor as作者: Exuberance 時間: 2025-3-23 05:47 作者: 分離 時間: 2025-3-23 13:22 作者: Bureaucracy 時間: 2025-3-23 15:04 作者: 纖細(xì) 時間: 2025-3-23 21:48 作者: Debility 時間: 2025-3-23 23:02 作者: genesis 時間: 2025-3-24 04:07 作者: 無關(guān)緊要 時間: 2025-3-24 10:20
Business Start-up Processes in Norway,immune cells, such as the discovery of IL-2 and production of monoclonal antibodies, fostered the development of novel techniques for studying the immune system and ultimately the development and approval of several cancer immunotherapies by the United States Food and Drug Association in the 1980s a作者: coalition 時間: 2025-3-24 14:17
Giuseppe Turchetti,Elie Geislerrticularly with the goal of generating Th1-promoting inflammation that stokes endogenous priming of antitumor CD8. T cells, is a growing area of clinical investigation. This approach is analogous to in situ vaccination, ultimately providing a personalized antitumor response against relevant tumor as作者: 單獨 時間: 2025-3-24 17:10
Giuseppe Turchetti,Elie Geisleras well as emerging antigens for which mounting evidence suggests their utility as targets for adoptive T cell therapy. We discuss the growing technological advancements that have facilitated sequence identification of such antigens and their cognate T cells, and applicability of such technologies i作者: Inordinate 時間: 2025-3-24 21:07 作者: synovial-joint 時間: 2025-3-25 02:00
Paolo Rosa,Claudio Sassanelli,Sergio Terziroach immune checkpoint inhibitors therapies to extend/maximize the treatment response as long as possible? How to overcome therapeutic resistance by specific concurrent immunomodulators or targeted therapy or chemotherapy? The role of immune checkpoint inhibitors in combination or sequencing with c作者: 變異 時間: 2025-3-25 04:19 作者: CYN 時間: 2025-3-25 08:43
Amrita Majumdar,Sudipta Majumdars from PSCs, together with the potential and perspectives of CAR-T, CAR-macrophages, and CAR-natural killer (NK) cells in cancer treatment. The combination of PSC-derived immune cells and CAR engineering will pave the way for developing next-generation cancer immunotherapy.作者: Terminal 時間: 2025-3-25 12:24 作者: cyanosis 時間: 2025-3-25 17:29 作者: instructive 時間: 2025-3-25 23:42
Development of Cancer Immunotherapies,h in the past several decades and a common treatment strategy for several cancer types. The concept of harnessing the immune system for this purpose originated over 100?years ago when a physician by the name of William Coley successfully treated several of his cancer patients with a combination of l作者: 叢林 時間: 2025-3-26 02:19
,Melanoma: An immunotherapy?journey from bench to bedside,therapies has been subjected to clinical trials in this disease, with limited success until the immune checkpoint blockade era. That revolution launched first in melanoma, heralded a landscape change throughout cancer that continues to reverberate today.作者: 欲望小妹 時間: 2025-3-26 07:16 作者: Inelasticity 時間: 2025-3-26 09:29 作者: 假裝是你 時間: 2025-3-26 12:42
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma,ncer immunotherapy. The impressive clinical responses seen in hematologic malignancies have led to the investigation of CAR T cells in solid tumors but attaining similar results has been challenging to date. Glioblastoma (GBM) presents a particularly challenging malignancy for treatment and despite 作者: Anthropoid 時間: 2025-3-26 17:29
Lag3: From Bench to Bedside,imited to a single cancer type. Promising results have been reported in various solid tumors, for example, lung cancer. The success of these drugs depends on the activation of tumor-infiltrating lymphocytes and primary and acquired resistance have been reported alongside a high rate of immune-relate作者: frivolous 時間: 2025-3-27 00:17
Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution,is revolutionizing the standard of care in certain patients with genitourinary malignancies. As modest clinical benefits of IL-2 for metastatic renal cell carcinoma and Bacillus Calmette-Guerin therapy for early-stage bladder cancers in the past years, immune checkpoint inhibitors therapies demonstr作者: coagulation 時間: 2025-3-27 05:12 作者: Eructation 時間: 2025-3-27 06:11
Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells,CAR-T therapy has been challenging due to labor some manufacturing processes for every patient, and the cost due to the complexity of the process. Moreover, T cell dysfunction results from the immunosuppressive tumor microenvironment in certain patients. Considering technical challenges in autologou作者: violate 時間: 2025-3-27 12:15 作者: Credence 時間: 2025-3-27 17:35 作者: osteopath 時間: 2025-3-27 20:27 作者: Synovial-Fluid 時間: 2025-3-27 23:12 作者: 集合 時間: 2025-3-28 03:28 作者: 新字 時間: 2025-3-28 10:05
978-3-030-96378-1The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: 無思維能力 時間: 2025-3-28 10:34 作者: Innocence 時間: 2025-3-28 17:56 作者: 走路左晃右晃 時間: 2025-3-28 22:15
Cancer Treatment and Researchhttp://image.papertrans.cn/c/image/221136.jpg作者: condemn 時間: 2025-3-29 02:31
Business Start-up Processes in Norway,h in the past several decades and a common treatment strategy for several cancer types. The concept of harnessing the immune system for this purpose originated over 100?years ago when a physician by the name of William Coley successfully treated several of his cancer patients with a combination of l作者: TSH582 時間: 2025-3-29 05:32 作者: 性上癮 時間: 2025-3-29 10:24
Giuseppe Turchetti,Elie Geislerentally depends upon context provided by the innate immune system, particularly antigen presenting cells. Such context is determined in large part by sensing of pathogen specific and damage associated features by pathogen recognition receptors (PRRs). PRR activation induces the delivery of T cell pr作者: 加入 時間: 2025-3-29 14:04
Giuseppe Turchetti,Elie Geislererred to patients with refractory cancers presenting such antigens. When such T cells are derived from healthy donors, they can be banked for off-the-shelf administration in appropriately tissue matched patients. Therefore, tumor antigen-specific, donor-derived T cells are expected to be a mainstay 作者: assail 時間: 2025-3-29 16:53
https://doi.org/10.1007/978-88-470-2838-8ncer immunotherapy. The impressive clinical responses seen in hematologic malignancies have led to the investigation of CAR T cells in solid tumors but attaining similar results has been challenging to date. Glioblastoma (GBM) presents a particularly challenging malignancy for treatment and despite 作者: Maximize 時間: 2025-3-29 21:18 作者: 令人心醉 時間: 2025-3-30 03:02 作者: Reverie 時間: 2025-3-30 07:52
